• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Introduction to 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine (CAS No. 928118-20-1)

4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine, identified by the Chemical Abstracts Service Number (CAS No.) 928118-20-1, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This bicyclic structure, featuring a fused pyridine and pyrazine ring system with a methyl substituent at the 4-position, presents a unique framework for exploring its biological activities and potential therapeutic applications.

The molecular architecture of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine makes it an intriguing candidate for further investigation due to its structural similarity to several known bioactive molecules. The presence of both nitrogen-containing rings suggests potential interactions with biological targets such as enzymes and receptors, which are pivotal in drug design. This compound belongs to the broader class of pyridopyrazine derivatives, which have been extensively studied for their pharmacological properties.

In recent years, there has been a surge in interest regarding novel heterocyclic compounds that exhibit promising biological activities. 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine has been explored in various preclinical studies for its potential role in modulating cellular pathways associated with neurological disorders, inflammation, and cancer. The compound's ability to interact with specific molecular targets has made it a subject of intense research in drug discovery programs.

One of the most compelling aspects of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine is its structural versatility. The pyridopyrazine core can be modified at multiple positions to tailor its pharmacological profile. Researchers have been particularly interested in exploring derivatives of this compound that exhibit enhanced binding affinity and selectivity for target proteins. This flexibility has allowed scientists to design analogs with improved solubility, metabolic stability, and pharmacokinetic properties.

The synthesis of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies have been employed to streamline the process, making it more efficient and scalable for industrial applications. The development of novel synthetic routes has not only facilitated the production of this compound but also provided insights into the structural modifications that can enhance its biological activity.

Recent studies have highlighted the potential of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine as an intermediate in the synthesis of more complex pharmacophores. Its scaffold can be functionalized to introduce various substituents that modify its electronic and steric properties. This adaptability has made it a valuable building block in medicinal chemistry campaigns aimed at discovering novel therapeutic agents.

The pharmacological evaluation of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine has revealed several interesting findings. In vitro assays have demonstrated its ability to inhibit certain enzymes and receptors involved in disease pathogenesis. For instance, preliminary data suggest that this compound may exhibit anti-inflammatory effects by modulating cytokine production and immune cell signaling pathways. Additionally, its interaction with specific neurotransmitter receptors has raised hopes for its potential use in treating neurological disorders.

The exploration of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine in animal models has provided further evidence of its biological significance. Studies in rodents have shown that this compound can cross the blood-brain barrier and exert therapeutic effects on central nervous system disorders. These findings are particularly encouraging for the development of new treatments for conditions such as depression and epilepsy.

As research progresses, the understanding of 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine continues to expand. New synthetic strategies are being developed to optimize its production, while computational methods are being employed to predict its binding interactions with biological targets. These advancements are expected to accelerate the discovery of novel derivatives with enhanced pharmacological properties.

The future prospects for 4-methyl-2,3-dihydro-1H-pyrido[2,3-b]pyrazine are bright, with ongoing studies aiming to elucidate its mechanism of action and explore new therapeutic applications. Collaborative efforts between academic researchers and pharmaceutical companies are likely to drive innovation in this area, leading to the development of next-generation drugs based on this promising scaffold.

• 794471-59-3(3,5-Pyridinediamine,2-(4-ethyl-1-piperazinyl)-)
• 72128-57-5(Pyrido[2,3-b]pyrazine,1,4-diethyl-1,2,3,4-tetrahydro-)
• 35808-40-3(1H,2H,3H,4H-pyrido[2,3-b]pyrazine)
• 111669-24-0(3-Pyridinamine,N-ethyl-2-(1-piperazinyl)-)
• 16019-67-3( )
• 5028-17-1(2-(4-Methyl-piperazin-1-yl)-pyridin-3-ylamine)
• 1242926-71-1(4-benzyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine)
• 87394-62-5(2-(piperazin-1-yl)pyridin-3-amine)
• 147539-21-7(3-Pyridinamine,N-(1-methylethyl)-2-(1-piperazinyl)-)
• 148441-28-5(2,3-Pyridinediamine, N2,N2,N3,N3-tetraethyl-6-(1-piperazinyl)-, hydrochloride (1:2))